BioSpace News Archive

IDBS has appointed Pietro Forgione as its new General Manager. Pietro has spent the last 16 years at IDBS with responsibilities for EMEA sales, Global Key Accounts, and most recently, as Vice President of Product, Strategy and Marketing.

Cloud-based digital pathology platform helps CRO deliver more informed preclinical studies

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the “Company” or “PreveCeutical”), is pleased to announce that on April 21, 2023, PreveCeutical created a new division to develop and train an Artificial Intelligence (AI) tool that will be capable of learning R&D, clinical trials, and other clinical information.

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugates (“ADCs”), is pleased to announce the issuance of its US patent no. 11,612,651 by the United States Patent and Trademark Office (USPTO).

The Insight Partners published latest research report on “Vision Care Market Share Report, Size, Segment, Scope & Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type and Distribution Channel”, the global market is expected to grow from USD 74,110.14 million in 2022 to USD 98,968.42 million by 2028; it is estimated to register a CAGR of 4.9% from 2022 to 2028.

Axitan, the UK biotech company focused on the elimination of antibiotics from animal feed, is pleased to announce the appointments of two new senior members to its UK and US teams:

Mydecine Innovations Group Inc. is glad to share promising pharmacokinetics and pharmacodynamics (“PKPD”) results from the MYCO-006 family in mouse models.

Justin Zenanko, CEO of SynerFuse™, is proud to announce that Michael Park, M.D., associate professor of neurosurgery at the University of Minnesota, SynerFuse IDE Proof of Concept study PI, presented data from the Proof of Concept study’s first eight patients at the 10th annual Minnesota Neuromodulation Symposium, April 21, 2023.

Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions, will report its financial results for the quarterly period ended March 31, 2023 after the close of the market on Monday, May 8, 2023.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced it placed No. 64 on the U.S. Environmental Protection Agency’s National Top 100 List of the largest green power users within the EPA’s Green Power Partnership program.